Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying ...

Arcturus, a new COVID-19 sub-variant, has caught the attention of the World Health Organization (WHO). The new omicron variant, XBB.1.16, causes familiar symptoms of previous variants of coronavirus.

The Arcturus subvariant stems from the Omicron strain of Covid-19 and is known as XBB.1.16 since it descends from the recombinant variant XBB, which combines two sublineages of Omicron BA.2.

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

The Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing ("Rospotrebnadzor") sees a risk of the increased incidence of infections with the Arcturus COVID-19 ...

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive has been approved for marketing in the EU, becoming the first based on self-amplifying mRNA (sa-mRNA) to clear that threshold. While ...

‘Arcturus’ XBB.1.16: CDC tracker and map show where the latest COVID-19 variant is spreading A new variant of COVID-19, unofficially nicknamed “Arcturus,” is spreading across America and ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...

The trial has been testing Vaxart’s oral vaccine candidate against an approved mRNA COVID-19 vaccine in adults previously ... on a March 20 earnings call. Arcturus confident of retaining BARDA ...

Numbers and graphics on this page will continue to update automatically but may become out of date as public health agencies wind down reporting of various COVID-19 metrics. This page tracks the ...

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...